Overall, there was a greater chance of observing any anti-peripheral nerve cell IgG or IgM antibody reactivity in the sera of patients with ZIKV-GBS (38.7%) and ZIKV-OND (33.3%), compared with noncomplicated ZIKV (ZIKV-CON) (10.4%) and non-ZIKV control (CON) (7.0%) groups (p = 0.0004, χ2 test). The gene discussed is CD40LG; the disease is Guillain-Barre syndrome.